AGIO Quote, Financials, Valuation and Earnings

Apellis Pharmaceuticals, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of -29.49%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Apellis Pharmaceuticals, Inc.'s return on equity of 8.48%.

Agios Pharmaceuticals, Inc. has a consensus price target of $43.75, signalling upside risk potential of 17.9%. On the other hand Apellis Pharmaceuticals, Inc. has an analysts' consensus of $38.60 which suggests that it could fall by -4.48%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Apellis Pharmaceuticals, Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Apellis Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.263% less volatile than S&P 500. In comparison Apellis Pharmaceuticals, Inc. has a beta of -0.189, suggesting its less volatile than the S&P 500 by 118.923%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Apellis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Apellis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than Apellis Pharmaceuticals, Inc. quarterly revenues of $199.9M. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Apellis Pharmaceuticals, Inc.'s net income of -$59M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Apellis Pharmaceuticals, Inc.'s PE ratio is 327.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 38.89x versus 5.12x for Apellis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Biogen, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of -2.24%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Biogen, Inc.'s return on equity of 7.36%.

Agios Pharmaceuticals, Inc. has a consensus price target of $43.75, signalling upside risk potential of 17.9%. On the other hand Biogen, Inc. has an analysts' consensus of $207.33 which suggests that it could grow by 16.74%. Given that Agios Pharmaceuticals, Inc. has higher upside potential than Biogen, Inc., analysts believe Agios Pharmaceuticals, Inc. is more attractive than Biogen, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.263% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.797%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than Biogen, Inc. quarterly revenues of $2.2B. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Biogen, Inc.'s net income of -$48.9M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Biogen, Inc.'s PE ratio is 19.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 38.89x versus 2.63x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of 34.53%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.

Agios Pharmaceuticals, Inc. has a consensus price target of $43.75, signalling upside risk potential of 17.9%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 37.71%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.263% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.264%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 38.89x versus 5.30x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -541.09% compared to Agios Pharmaceuticals, Inc.'s net margin of 34.4%. Agios Pharmaceuticals, Inc.'s return on equity of -30.11% beat Eli Lilly & Co.'s return on equity of 104.39%.

Agios Pharmaceuticals, Inc. has a consensus price target of $43.75, signalling upside risk potential of 17.9%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Eli Lilly & Co. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Agios Pharmaceuticals, Inc..

Agios Pharmaceuticals, Inc. has a beta of 0.787, which suggesting that the stock is 21.263% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Agios Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Agios Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agios Pharmaceuticals, Inc. quarterly revenues are $20M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Agios Pharmaceuticals, Inc.'s net income of -$108M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Agios Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.91x while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals, Inc. is 38.89x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.